skip to content

Improving dose-finding methods in clinical development: design, adaptation, and modeling

Presented by: 
J Pinheiro [Johnson & Johnson]
Tuesday 16th August 2011 - 12:00 to 12:30
INI Seminar Room 1
Session Title: 
Dose ranging: Industry challenges
Session Chair: 
Vlad Dragalin
The pharmaceutical industry experiences increasingly challenging conditions, with a combination of escalating development costs, tougher regulatory environment, expiring patents on important drugs, and fewer promising drugs in late stage of development. Part of this pipeline problem is attributed to poor dose selection for confirmatory trials leading to high attrition rates (estimated at 50%) for Phase 3 programs. Improving the efficiency of drug development, in general, and of dose-finding studies in particular, is critical for the survival of the industry. A variety of methods have been proposed to improve dose selection and, more broadly, understanding of the dose-response relationship for a compound. Among them: adaptive designs, modeling and simulation approaches, optimal designs, and clinical utility indices. In this talk we’ll discuss and illustrate the utilization of some of those approaches in the context of dose-finding trials. The results of a comprehensive se t of simulation studies conducted by the PhRMA working group on Adaptive Dose-Ranging Studies will be used to discuss the relative merits of the various approaches and to motivate recommendations on their use in practice.
The video for this talk should appear here if JavaScript is enabled.
If it doesn't, something may have gone wrong with our embedded player.
We'll get it fixed as soon as possible.
Presentation Material: 
University of Cambridge Research Councils UK
    Clay Mathematics Institute London Mathematical Society NM Rothschild and Sons